ESPE2014 Poster Presentations Diabetes (2) (11 abstracts)
Nutritional Status and Respiratory Function in Patients Affected by Cystic Fibrosis and Glucose Metabolism Derangements after 4 Years of Insulin Therapy with Glargine
Enza Mozzillo a, , Valeria Raia a , Valentina Fattorusso a , Carla Cerrato a , Elena De Nitto a , Fabiola De Gregorio a , Angela Sepe a , Giuliana Valerio b & Adriana Franzese a
aSection of Pediatrics, Department of Translational Medical Science, University of Naples Federico II, Naples, Italy; bDepartment of Movement Sciences, Parthenope University of Naples, Naples, Italy
Background: The glucose metabolism derangements (GMD) can have an important impact on nutritional status and respiratory function in patients with cystic fibrosis (CF).
Objective and hypotheses: The aim of our study is to evaluate the effects of 4 years of glargine therapy in patients affected by CF and GMD.
Method: All CF patients attended to the Center of Cystic Fibrosis of our department were screened by oral glucose tolerance test. All CF subjects showing the following GMD were enrolled into a protocol of treatment with insulin glargine: cystic fibrosis related diabetes (CFRD), patients with glycemia at T0′ >126 mg/dl and/or T120′ >200 mg/dl; impaired glucose tolerance (IGT), patients with glycemia at T120′ >140 mg/dl; abnormal glucose tolerance (AGT), patients with glycemia at T30′ and/or T60′ and/or T90′ >140 mg/dl. The starting dose was 0.2 UI/kg per day. Eighteen patients with GMD (6-CFRD, 6-IGT, 6-AGT), mean age 10.7±2.4 years at the beginning of the study, completed 4 years of treatment with glargine (average dose: 0.22 IU/kg per day, range: 0.11–0.24). BMI, BMI Z-score, forced expiratory volume in the first second (FEV1%) and number of respiratory exacerbations/year were assessed longitudinally by 2 years before the beginning of therapy to 4 following years.
Results: Longitudinal alterations of analysed parameters (mean±S.D.) are in the table.
| −2 years | −1 years | 0 | +1 years | +2 years | +3 years | +4 years | P | |
| BMI | 16.3±2.5 | 16.5±2.4 | 17.1±2.5 | 18±2.7 | 18.7±2.6 | 19.1±2.5 | 19.4±2.5 | <0.05 |
| BMIz-s | −0.3±1.1 | −0.3±0.9 | −0.2±0.8 | −0.1±0.9 | −0.07±0.8 | −0.1±0.7 | −0.2±0.7 | ns |
| FEV1% | 95.3±3.4 | 93.1±17.8 | 91.6±19.2 | 94.7±19 | 91.9±18.3 | 91.1±21.6 | 94.3±15.3 | ns |
| Exac/year | 2±1.4 | 1.9±1.5 | 1.5±1 | 1.3±1.1 | 1.5±1.2 | 1.3±1.3 | 1.1±1.2 | <0.05 |
Conclusion: Glargine treatment seems to reduce the number of pulmonary exacerbations in patients affected by CF and GMD; moreover it seems to retard the decay of nutritional parameters and of respiratory function.
Article tools
My recent searches
My recently viewed abstracts
Authors
ESPE Abstracts
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more